CANTARGIA AB
Developing antibody-based drugs targeting IL1RAP for serious diseases.
Overview
- 20–49
- Employees
- ≤1K SEK
- Revenue
- 2009
- Founded
Key Decision Makers
Hilde H. Steineger
CEO
Wolfram Dempke
Chief Medical Officer
Magnus Persson
Chairman of the Board
Damian Marron
Board Member
+6 more contacts in Funnelfeedr
Description
Cantargia is a biotechnology company focused on developing innovative antibody-based therapeutics. Their primary scientific target is the protein IL1RAP, which plays a role in several serious conditions. The company's mission is to create treatments for cancer as well as autoimmune and inflammatory...